Allogeneic cytotoxic T-cell therapy (University of Edinburgh)

N/A

Report date: 2023/04/23 15:18:09

Base Information

Drug NameAllogeneic cytotoxic T-cell therapy (University of Edinburgh)

Drug Alias NameT-cell therapy (post-transplant lymphoproliferative disease)

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Cytotoxic T-lymphocytes therapy

Mechanisms of ActionUpdating

TargetsNot applicable

Therapy Area/IndicationsLymphoproliferative Disorders

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 3 Clinical)

Highest Status in ChinaN/A

Originator CompaniesThe University Of Edinburgh

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesThe University Of Edinburgh

Active IndicationsN/A

Inactive IndicationsLymphoproliferative Disorders

Other Information

ATC CodeN/A